neuroFix Therapeutics Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
1
neuroFix Therapeutics General Information
Description
Developer of therapeutic products. The company develops NFC-1 a non-stimulant metabotropic glutamate receptor for the treatment of mGluR network mutation positive attention deficit hyperactivity disorder and neuropsychiatric symptoms in USA.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
- DE
- United States
neuroFix Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
neuroFix Therapeutics Patents
neuroFix Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-1199297-A | Spinal osteosynthesis device | Inactive | 05-Mar-1996 | 00000000000 | |
| EP-0884979-A1 | Spinal osteosynthesis device | Inactive | 05-Mar-1996 | 00000000000 | |
| FR-2745707-B1 | Spinal osteosynthesis device | Inactive | 05-Mar-1996 | 00000000000 | |
| FR-2745707-A1 | Spinal osteosynthesis device | Active | 05-Mar-1996 | A61B17/7026 | 0 |
neuroFix Therapeutics Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Hakon Hakonarson Ph.D | Founder |